J&J/Bayer to pursue secondary CV prevention in ACS label for Xarelto
This article was originally published in Scrip
Johnson & Johnson and its partner Bayer Healthcare Pharmaceuticals have said they are planning to file for approval of the oral Factor Xa inhibitor, Xarelto (rivaroxaban), in the additional indication of secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS) by the end of this year.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.